)
)
Tango Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Tango Therapeutics Inc
Access all reports
Tango Therapeutics Inc. is a biotechnology firm focused on the discovery and development of innovative treatments for cancer. The company's research is centered on creating drugs that target specific genetic vulnerabilities in cancer cells. One of its leading projects, TNG908, is a synthetic lethal small molecule inhibitor designed for treating cancers characterized by methylthioadenosine phosphorylase deletions. Additionally, Tango Therapeutics is developing several other compounds, including TNG462 for similar indications, TNG260 targeting repressor element-1 silencing transcription, TNG348 aimed at BRCA1 or BRCA2-mutant cancers, and another compound targeting STK11-mutant cancers. The company is based in Boston, Massachusetts and its shares are listed on the Nasdaq.
Key slides for Tango Therapeutics Inc
Corporate Presentation
Tango Therapeutics Inc
Corporate Presentation
Tango Therapeutics Inc
Latest articles
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Ticker symbol
TNGX
Country
🇺🇸 United States